Trial reportDiabetes & metabolic syndrome
Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India.
Trial report in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis.The Journal of laryngology and otology · 2022Pooled it
- Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis.Mycopathologia · 2022Pooled it
- Risk factors for mucormycosis among diabetic individuals, Bathinda, Punjab: a case-control study.BMC infectious diseases · 2026Article
- Association between SARS-CoV-2 viral load and serum biomarkers with mortality in Mexican patients.Journal of education and health promotion · 2025Article
- Article
- Covid-19-Associated Mucormycosis: Histopathology of the Deadly Fungal Infection.International archives of otorhinolaryngology · 2024Article
- Article
- COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.Mycopathologia · 2023Article
- Imaging spectrum in rhino-orbito-cerebral mucormycosis: a cross-sectional study.Annals of medicine and surgery (2012) · 2023Article
- Article
- COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023Review
- Article
- Glycemic Control in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Mucormycosis in a Patient with Severe COVID-19 Disease-The First Case Report in Romania and a Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
- Onset of Mucormycosis in Patients with COVID-19: A Systematic Review on Patients' Characteristics.European journal of dentistry · 2023Article
- Spotlight on the Mucormycosis Outbreak: A Deadly Fungal Infection That Followed the COVID-19 Pandemic.Cureus · 2023Article
- Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review.Indian journal of ophthalmology · 2023Review
- Maxillary mucormycosis and concurrent osteomyelitis in a post-COVID-19 patient with new onset diabetes mellitus.Proceedings (Baylor University. Medical Center) · 2023Article
- Selection of Ideal Reference Genes for Gene Expression Analysis in COVID-19 and Mucormycosis.Microbiology spectrum · 2022Article
- Clinical Phenotypes of COVID-19 Associated Mucormycosis (CAM): A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDiabetes Mellitus predisposes patients to invasive fungal infections. There has been a recent surge of Mucormycosis with COVID 19 infection particularly in patients with diabetes. This study aims to study the clinical spectrum of CAM (COVID -associated Mucormycosis) with diabetes and subsequent outcomes. MATERIAL AND
methodsThis was a descriptive study conducted at a single COVID Care Centre in India in patients with COVID Associated Mucormycosis from April 12, 2021 to May 31, 2021.
resultsAmong 953 hospitalized patients with COVID 19 infection, 32 patients had CAM with an incidence of 3.36%. In patients with CAM, 87.5% had Diabetes Mellitus as the most common co-morbidity. The majority of the patients had poor glycemic control with a mean HbA1c of 9.06%. Out of the total study population, 93% had prior exposure to high dose corticosteroids. During the study period, 12.5% patients of CAM did not survive.
conclusionMucormycosis is an angioinvasive fungal infection with high mortality. The disease has surged in COVID 19 pandemic due to uncontrolled diabetes and improper corticosteroid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.